BF
KRYS icon

BOK Financial’s Krystal Biotech KRYS Stock Holding History

BOK Financial’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$585K Sell
1,573
-256
-14% -$76.5K 0.01% 530
2026
Q1 		$472K Buy
+1,829
New +$487K 0.01% 552
2024
Q4 		– Sell
-2
Closed -$352 – 1393
2024
Q3 		$352 Buy
+2
New +$386 ﹤0.01% 1258

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BOK Financial's KRYS Position: Q2 2026 in Review

BOK Financial reduced its Krystal Biotech (KRYS) stake by 14% in Q2 2026, selling an estimated $76.5K and leaving 1,573 shares worth $585K. The position accounts for 0.01% of the portfolio, ranked #530.

BOK Financial first reported a position in KRYS in Q3 2024 and has held it in 3 quarters since. 424 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • BOK Financial held 1,573 shares of Krystal Biotech worth $585K as of Q2 2026.
  • BOK Financial sold 256 Krystal Biotech shares in Q2 2026, an estimated $76.5K.
  • Krystal Biotech made up 0.01% of BOK Financial's portfolio in Q2 2026, its #530 holding.
  • BOK Financial first reported a position in Krystal Biotech in Q3 2024 and has held it in 3 quarters since.
  • 424 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on BOK Financial's 13F filing for Q2 2026, filed 10 Aug 2026.